SCHEMBL14033895

SCHEMBL14033895

Nc1ncc(-c2cccnc2)c2scc(-c3cccc(NC(=O)Nc4ccc(C(F)(F)F)cc4)c3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 17/20 1.00
KDR P35968 3/20 0.73
CYP3A4 P08684 1/20 0.73
PLK4 O00444 1/20 0.67
AURKA O14965 1/20 0.67
MAPK13 O15264 1/20 0.67
PDPK1 O15530 1/20 0.67
JAK2 O60674 1/20 0.67
CHEK2 O96017 1/20 0.67
ABL1 P00519 1/20 0.67
NTRK1 P04629 1/20 0.67
INSR P06213 1/20 0.67
LCK P06239 1/20 0.67
FYN P06241 1/20 0.67
CSF1R P07333 1/20 0.67
LYN P07948 1/20 0.67
MET P08581 1/20 0.67
KIT P10721 1/20 0.67
PIM1 P11309 1/20 0.67
FGFR1 P11362 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5102510 0.90 BRAF (1.00) BRAFKDRCYP3A4PLK4AURKA
SCHEMBL5101962 0.90 BRAF (1.00) BRAFKDRCYP3A4AURKB
SCHEMBL5098615 0.88 BRAF (1.00) BRAFKDRCYP3A4
SCHEMBL3526961 0.88 BRAF (0.78) BRAFKDRCYP3A4PLK4AURKA
SCHEMBL5101957 0.86 BRAF (1.00) BRAFKDRCYP3A4
SCHEMBL3527326 0.86 KDR (0.88) BRAFKDRCYP3A4PLK4AURKA
SCHEMBL4819011 0.86 BRAF (1.00) BRAFKDRCYP3A4
SCHEMBL3527384 0.85 KDR (0.76) BRAFKDRCYP3A4PLK4AURKA
SCHEMBL1694775 0.84 KDR (0.97) BRAFKDRCYP3A4PLK4AURKA
SCHEMBL233442 0.84 KDR (1.00) BRAFKDRCYP3A4PLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-10-16 US disclosed
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-10-16 US disclosed
WO-2007056625-A2 THIENOPYRIDINE B-RAF KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors BRAF, RAF1, ARAF BRAF 1/4885KDR 423/4885CYP3A4 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.